Advertisement

Immunotherapeutical Strategies in Cancer Patients

  • Irene Munno
  • Claudio De Simone
  • Vito Covelli
  • Emilio Jirillo
  • Salvatore Antonaci
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 267)

Abstract

Individuals bearing tumors belong to the category of immunocompromised subjects. In fact, these patients exhibit multiple deficits of their immune responsiveness either in terms of acquired immune response or in terms of phagocytic functions1. The above immune dysfunctions may depend on several factors2 such as:
  1. i.

    Suppressive factors released by the same neoplasia;

     
  2. ii.

    A primary condition of immune alteration in a given subject which may be responsible for the development of the neoplasia. In this respect, individuals affected by congential immunodeficiencies or secondary immune deficits (e.g. transplanted patients or uremic subjects) undergo cancer with higher frequency than patients who had no clear evidence of immune alterations before the discovery of cancer;

     
  3. iii.

    Chemotherapy and radiotherapy represent an additional cause of immune suppression in neoplastic patients.

     

Keywords

Natural Killer Cell Lactic Acid Bacterium Bacillus Calmette Guerin Acetic Acid Bacterium Lepromatous Leprosy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nelson, D.S., Nelson, M., Farram E., Inoue Y. Cancer and subversion of host defences. Aust. J. Exp. Biol. Med. 59: 229 (1981).CrossRefGoogle Scholar
  2. 2.
    Penn I. Depressed immunity and the development of cancer. Clin. Exp. Immunol. 46: 459 (1981).PubMedGoogle Scholar
  3. 3.
    Easmon, C.S.F. and Gaya,H. (Eds.). The second international symposium on infections in the immunocompromised host. Academic Press, London (1983).Google Scholar
  4. 4.
    Fudenberg, H.H., and Smith, L. Immunomodulation and immunotherapy: an overview of biologic and synthetic agents and their effects on the immune system. EOS J. Immunol. Immunopharmacol. 1: 3 (1981).Google Scholar
  5. 5.
    Bast, R.C., Zbar, B., Borsos, T., and Rapp, H.J. BCG and cancer. N. Engl. J. Med. 290: 1458 (1974).PubMedCrossRefGoogle Scholar
  6. 6.
    Rosenberg, R.A. The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2. Semin. Oncol. 13: 200 (1986).PubMedGoogle Scholar
  7. 7.
    Tanneberger, S., Lenk, H., Müller,V., Ebert, J., and Shiga T. Human pharmacological investigation of a recombinant human tumor necrosis factor preparation. A phase I trial and preliminary results of a phase II trial, in: “Tumor Necrosis Factor/Cachectin and Related Cytokines”, Bonavida, B., Gifford, G.E., Kirchner, H., and Old, L.J., eds., p. 205, Karger, Basel (1988).Google Scholar
  8. 8.
    Covelli,V., and Jirillo, E. Neuropeptides with immunoregulatory functions: current status of investigation. Funct. Neurol. 3: 253 (1988).PubMedGoogle Scholar
  9. 9.
    Gupta, S. Immunotherapy of human immunodeficiency virus infection. EOS J. Immunol. Immunopharmacol. 8: 231 (1988).Google Scholar
  10. 10.
    Hamada, S., and Slade H.D. Biology, immunology and cariogenicity of Streptococcus mutans. Microbiol. Rev. 44: 331 (1980).PubMedGoogle Scholar
  11. 11.
    De Simone,C., Jirillo, E., Bianchi-Salvadori, B., Baldinelli, L., Tzantzoglou, S., Di Fabio, S., Grassi, P.P., and Vesely, R. Stimulation of host resistance by a diet supplemented with yogurt, in: “Immunomodulators and Non-Specific Host Defence Mechanisms Against Microbial Infections, Masihi, K.N., and Lange, W., eds. p. 279, Pergama7 Press, Oxford (1988).Google Scholar
  12. 12.
    Jirillo, E., Michalek, S.M., and McGhee, J.R. Lipopolysaccharide regulation of the immune response: LPS effects on lymphoreticular cells and mucosal immune responses. EOS J. Immunol. Immunopharmacol. 4: 21 (1984).Google Scholar
  13. 13.
    Jirillo, E., Miragliotta, G., Caretto, G., Cedola, M.C., Nappi, R., Sansone, L.A., Galanos, C., Antonaci, S. Relationship between immune system and gram-negative bacteria. Acid-treated Salmonella minnesota R 595 (Re) enhances immune responsiveness in patients with gynaecologié malignancies. Int. J. Immunopharmac. 8: 881 (1986).CrossRefGoogle Scholar
  14. 14.
    Jirillo, E., Munno, I., Pellegrino, N.M., Grassi, P.P., Maffione, A.B., Catino, A.M., Jirillo, A., and Antonaci, S. Immunotherapeutic approach to cancer and leprosy patients, in: “Molecular Aspects of Human Disease”, Gorrod, J.W., Albano, O., and Papa, S, eds. p. 240, Ellis Horwood Limited, Chicherster, England (1989).Google Scholar
  15. 15.
    Sztein, M.B., and Goldstein, A.L. Thymic hormones. A clinical update. Springer Semin. Immunopathol. 9: 1 (1986).Google Scholar
  16. 16.
    Munno I., Pellegrino, N.M., Fumo, G., Barbieri, G., Poli-Meno, G., De Filippis, V., and Jirillo,E. Effects of a synthetic extract (thymopentin) on the immune system of lepromatous leprosy patients. Cytobios 52: 167 (1987).PubMedGoogle Scholar
  17. 17.
    Munno, I., Pellegrino, N.M., Di Vagno, G., Nappi, R., and Jirillo, E. Effect of thymopentin pentapeptide (TP-5) on the immune system of patients with gynecological malignancies. EOS J.Immunol. Immunopharmacol. 7: 117 (1987).Google Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Irene Munno
    • 1
  • Claudio De Simone
    • 2
  • Vito Covelli
    • 3
  • Emilio Jirillo
    • 1
  • Salvatore Antonaci
    • 4
  1. 1.ImmunologiaUniversity of BariBariItaly
  2. 2.Malattie InfettiveUniversità dell’ Aquila degli AbruzziL’ AquilaItaly
  3. 3.Neuro-anatomia ClinicaUniversity of BariBariItaly
  4. 4.Fisiopatologia Medica IUniversity of BariBariItaly

Personalised recommendations